{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:00:38Z","timestamp":1791612038264,"version":"4.3.4"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity is a complex metabolic disorder with significant implications for both individual and public health. It has been strongly linked to chronic headache conditions, including migraines and idiopathic intracranial hypertension (IIH). Individuals with obesity who suffer from migraine are at increased risk of chronification, while weight reduction has been associated with improvement in IIH-related headaches, likely due to a decrease in cerebrospinal fluid pressure. These observations underscore the importance of weight management strategies as a therapeutic consideration in patients with obesity and headache disorders. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are pharmacological agents that mimic the hormone's endogenous activity. Analysis of selected studies highlights that these agents have emerged as a promising therapeutic option. The aim of this narrative review is to examine the role of GLP-1 RAs in the management of headaches, particularly in the context of IIH, migraine, and the gut\u2013brain axis. Additionally, this review addresses the challenges associated with the use of this pharmaceutical class, including the potential for headaches as adverse effect, and identifies existing knowledge gaps that may guide future research.<\/jats:p>","DOI":"10.1055\/s-0045-1812303","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:53:23Z","timestamp":1761609203000},"page":"001-007","source":"Crossref","is-referenced-by-count":1,"title":["Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-0748","authenticated-orcid":false,"given":"Erika Tavares","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Consult\u00f3rio privado, Jaragu\u00e1 do Sul SC, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0492-2739","authenticated-orcid":false,"given":"Leidys Marina Pedrozo","family":"Garcia","sequence":"additional","affiliation":[{"name":"Consultorio privado, Valledupar, Cesar, Colombia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-4739","authenticated-orcid":false,"given":"Renata Gomes","family":"Londero","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Servi\u00e7o de Neurologia, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"D Furman","year":"2019","journal-title":"Nat Med"},{"issue":"06","key":"ref2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/oby.21107","article-title":"GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond","volume":"23","author":"D Ryan","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"02","key":"ref3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/head.12296","article-title":"Obesity and headache: part I\u2013a systematic review of the epidemiology of obesity and headache","volume":"54","author":"N C Chai","year":"2014","journal-title":"Headache"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/head.12297","article-title":"Obesity and headache: Part II\u2013potential mechanism and treatment considerations","volume":"54","author":"N C Chai","year":"2014","journal-title":"Headache"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fendo.2012.00141","article-title":"Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction","volume":"3","author":"M J Moon","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"08","key":"ref6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"J Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"ref7","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"S E Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"06","key":"ref8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.2040-1124.2012.00241.x","article-title":"Glucagon-like peptide-1 receptor agonists and their effects on weight reduction","volume":"3","author":"S J Shin","year":"2012","journal-title":"J Diabetes Investig"},{"issue":"04","key":"ref9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"C H\u00f6lscher","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/CPJ.0000000000001063","article-title":"The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight","volume":"11","author":"S P Mollan","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"X Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-021-01302-x","article-title":"Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation","volume":"22","author":"F Jing","year":"2021","journal-title":"J Headache Pain"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.14336\/AD.2019.0303","article-title":"Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","volume":"10","author":"L Gao","year":"2019","journal-title":"Aging Dis"},{"issue":"08","key":"ref14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.ijo.0800657","article-title":"Serum leptin, food intake and preferences for sugar and fat in obese women","volume":"22","author":"L J Karhunen","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp.71.1.1","article-title":"Idiopathic intracranial hypertension: any light on the mechanism of the raised pressure?","volume":"71","author":"R WH Walker","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"ref16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.ebiom.2015.07.029","article-title":"Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians","volume":"2","author":"Y Arai","year":"2015","journal-title":"EBioMedicine"},{"issue":"01","key":"ref17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review","volume":"25","author":"W Halloum","year":"2024","journal-title":"J Headache Pain"},{"issue":"11","key":"ref18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1212\/WNL.0000000000201076","article-title":"Clinical significance and therapeutic management of weight loss in patients with idiopathic intracranial hypertension","volume":"99","author":"J Hoffmann","year":"2022","journal-title":"Neurology"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2009.06.030","article-title":"Idiopathic intracranial hypertension is associated with lower body adiposity","volume":"117","author":"A Kesler","year":"2010","journal-title":"Ophthalmology"},{"issue":"01","key":"ref20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14737175.2023.2173575","article-title":"Migraine and obesity: what is the real direction of their association?","volume":"23","author":"S R Jahromi","year":"2023","journal-title":"Expert Rev Neurother"},{"issue":"02","key":"ref21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/02688690701827340","article-title":"Idiopathic intracranial hypertension: can studies of obesity provide the key to understanding pathogenesis?","volume":"22","author":"L Y Ooi","year":"2008","journal-title":"Br J Neurosurg"},{"issue":"404","key":"ref22","doi-asserted-by":"publisher","first-page":"eaan0972","DOI":"10.1126\/scitranslmed.aan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"H F Botfield","year":"2017","journal-title":"Sci Transl Med"},{"issue":"05","key":"ref23","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"J L Mitchell","year":"2023","journal-title":"Brain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"137397","DOI":"10.1186\/s10194-021-01302-x","article-title":"GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model","volume":"812","author":"F Jing","year":"2023","journal-title":"Neurosci Lett"},{"issue":"08","key":"ref25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.4103\/1673-5374.389626","article-title":"Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain","volume":"19","author":"Y Diz-Chaves","year":"2024","journal-title":"Neural Regen Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"T D Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"issue":"07","key":"ref27","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/clinem\/dgad076","article-title":"GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"108","author":"M Banerjee","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9951","key":"ref28","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"K M Dungan","year":"2014","journal-title":"Lancet"},{"issue":"06","key":"ref29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","article-title":"Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial","volume":"2","author":"M Diamant","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"08","key":"ref30","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"M Nauck","year":"2014","journal-title":"Diabetes Care"},{"issue":"01","key":"ref31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11096-021-01330-2","article-title":"Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020","volume":"44","author":"A Alsuhibani","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"04","key":"ref32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1590\/S0004-282","article-title":"Primary headaches in obese patients","volume":"63","author":"M FP Peres","year":"2005","journal-title":"Arq Neuro-Psiquiatria"},{"issue":"01","key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"01","key":"ref34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-023-01631-z","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"N Krajnc","year":"2023","journal-title":"J Headache Pain"},{"issue":"01","key":"ref35","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database","volume":"68","author":"W Lu","year":"2025","journal-title":"Eur Psychiatry"},{"issue":"07","key":"ref36","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/ph17070828","article-title":"Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis","volume":"17","author":"L Liu","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"06","key":"ref37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14656566.2024.2349791","article-title":"Pharmacological management of migraine: current strategies and future directions","volume":"25","author":"L Pellesi","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"01","key":"ref38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","article-title":"Combining treatments for migraine prophylaxis: the state-of-the-art","volume":"25","author":"L Pellesi","year":"2024","journal-title":"J Headache Pain"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1812303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:53:29Z","timestamp":1761609209000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1812303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["s00451812303"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1812303","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}